Tag: industry trends

Risk Scenarios and Sensitivity Analyses for Pricing, Reimbursement & HTA Interfaces The landscape of drug pricing, reimbursement, and Health Technology Assessment (HTA) has become increasingly complex, necessitating a thorough understanding of various risk scenarios and their implications for electronic data capture in clinical trials. This article serves as a step-by-step tutorial guiding clinical operations, regulatory…

Read More “Risk Scenarios and Sensitivity Analyses for Pricing, Reimbursement & HTA Interfaces” »

Regulatory and Policy Shifts Reshaping Pricing, Reimbursement & HTA Interfaces in the US, EU and UK Regulatory and Policy Shifts Reshaping Pricing, Reimbursement & HTA Interfaces in the US, EU and UK Introduction to the Evolving Landscape of Clinical Trials The biopharmaceutical and clinical research industry is undergoing substantial changes, particularly in the domains of…

Read More “Regulatory and Policy Shifts Reshaping Pricing, Reimbursement & HTA Interfaces in the US, EU and UK” »

Using Real-World Data to Inform Pricing, Reimbursement & HTA Interfaces Decisions Using Real-World Data to Inform Pricing, Reimbursement & HTA Interfaces Decisions Introduction to Real-World Data in Clinical Trials The integration of real-world data (RWD) into clinical trials signifies a paradigm shift in the biomedical research landscape. Real-world data encompasses information gathered outside of conventional…

Read More “Using Real-World Data to Inform Pricing, Reimbursement & HTA Interfaces Decisions” »

Governance Models and Cross-Functional Ownership for Pricing, Reimbursement & HTA Interfaces The integration of governance models and cross-functional ownership in pricing, reimbursement, and Health Technology Assessment (HTA) processes has increasingly become a focal point in the biopharmaceutical industry. As clinical trials evolve, stakeholders must remain agile and informed to navigate the complexities involved in determining…

Read More “Governance Models and Cross-Functional Ownership for Pricing, Reimbursement & HTA Interfaces” »

Pricing, Reimbursement & HTA Interfaces: What Clinical Leaders Need to Know Now Pricing, Reimbursement & HTA Interfaces: What Clinical Leaders Need to Know Now In the evolving landscape of clinical research, understanding the interplay between pricing, reimbursement, and Health Technology Assessment (HTA) is essential for clinical leaders. As clinical trials evolve, efficient management of economic…

Read More “Pricing, Reimbursement & HTA Interfaces: What Clinical Leaders Need to Know Now” »

How to Model Pricing, Reimbursement & HTA Interfaces for Global Study Portfolios How to Model Pricing, Reimbursement & HTA Interfaces for Global Study Portfolios In the competitive landscape of clinical research, understanding how to effectively model pricing, reimbursement, and Health Technology Assessment (HTA) interfaces is crucial for the successful design and execution of global study…

Read More “How to Model Pricing, Reimbursement & HTA Interfaces for Global Study Portfolios” »

Pricing, Reimbursement & HTA Interfaces in Practice: Benchmarks, Case Studies and Playbooks Pricing, Reimbursement & HTA Interfaces in Practice: Benchmarks, Case Studies and Playbooks Introduction to Pricing, Reimbursement, and HTA in Clinical Trials The integration of pricing, reimbursement, and Health Technology Assessment (HTA) considerations into clinical trial design is paramount, particularly in the context of…

Read More “Pricing, Reimbursement & HTA Interfaces in Practice: Benchmarks, Case Studies and Playbooks” »

High-Impact Pricing, Reimbursement & HTA Interfaces Strategies That Protect Trial Timelines and Margins High-Impact Pricing, Reimbursement & HTA Interfaces Strategies That Protect Trial Timelines and Margins Introduction to Clinical Trial Economics The landscape of clinical research is becoming increasingly complex, particularly in terms of economic considerations. High-impact pricing strategies, along with reimbursement processes and Health…

Read More “High-Impact Pricing, Reimbursement & HTA Interfaces Strategies That Protect Trial Timelines and Margins” »

Linking Pricing, Reimbursement & HTA Interfaces to Market Access, HTA and Payer Expectations Linking Pricing, Reimbursement & HTA Interfaces to Market Access, HTA and Payer Expectations The successful integration of pricing, reimbursement, and Health Technology Assessment (HTA) into the market access strategy is paramount for biopharmaceutical companies aiming to secure a successful launch for their…

Read More “Linking Pricing, Reimbursement & HTA Interfaces to Market Access, HTA and Payer Expectations” »